ENGN:NASDAQ, enGene Holdings Inc.

Why ENGN stock fell on November 16

enGene Holdings Inc. fell 21.6% on Monday, November 16, 2026, on 1,994,400 shares. No headline about ENGN came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.

ENGN stock overview

enGene Holdings Inc. (ENGN:NASDAQ) closed at $1.74 on November 20, 2026, down 1.14% on the day. The stock trades 85.8% below its 52-week high of $12.25 and 24.3% above its 52-week low of $1.40. Over the past year, it lost 76.5%. enGene Holdings Inc. is part of the Financials sector.

Key figures

Price
$1.74
Day change
-1.14%
Volume
556,716
Average volume
1,111,818
Market cap
116M+
52-week range
$1.40 – $12.25
50-day average
$1.79
200-day average
$3.79

Price action over the past year

In 252 trading sessions since November 20, 2025, ENGN closed higher on 122 days (48%). Its best day was November 12, 2026 (+26.67%) and its worst was May 7, 2026 (-80.56%). The stock moved 10% or more in a single session 13 times. It opened at least 5% above the previous day's high 1 time.

Recent signals

ENGN news

About enGene Holdings Inc.

enGene Holdings Inc. is a holding company. The Company, through its subsidiary, enGene Inc., is engaged in developing non-viral gene therapies based on localized delivery of nucleic acid payloads to mucosal tissues. The Company¿s proprietary dually derived chitosan (DDX) platform has a high degree of payload flexibility, including DNA and various forms of RNA with broad tissue and disease application. In preclinical animal and in vitro models, the Company¿s DDX technology has been demonstrated to effectively induce expression of therapeutic genes following delivery to the lung, gastrointestinal tract, and urinary tract, and its lead product detalimogene voraplasmid (EG-70) is being developed for the treatment of bacillus calmette-guerin (BCG)-resistant non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). EG-70 is a novel non-viral gene therapy designed to elicit a local immune response following the delivery to the bladder urothelium.

Similar stocks

Find more stocks like ENGN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.